
- GMP
- ISO 9001
About
Philogen is a Swiss-Italian biotechnology company founded in 1996 that discovers, manufactures, and develops targeted drugs for cancer and other serious conditions. It operates from sites in Italy and Switzerland and runs work from discovery through clinical development.
Services
Target discovery
Identifies accessible disease targets and discovers antibodies and small organic ligands.
Assays & in vitro testing
Ligand screening through discovery collaborations
Offers flexible collaboration structures for screening binders against one or multiple targets using proprietary discovery platforms.
Assays & in vitro testing
DNA-encoded library discovery
Uses DNA-encoded chemical libraries for fast and cost-effective drug discovery.
Assays & in vitro testing
Antibody discovery
Uses antibody phage libraries to isolate fully human monoclonal antibodies against antigens of interest.
Assays & in vitro testing
Cyclic peptide discovery
Uses proprietary phage libraries of short cyclic peptides for screening and binder isolation.
Assays & in vitro testing
Prototype development
Couples targeting ligands with bioactive payloads to generate targeted drug candidates.
Assays & in vitro testing
Preclinical evaluation
Tests targeted drugs in preclinical models.
ADME, DMPK & toxicology
Cell line development
Provides customized activities for cell line development in collaboration settings.
Cell line development
GMP manufacturing
Manufactures investigational medicinal products and commercial products in its GMP facilities near Siena.
CDMO: development & manufacturing
Manufacturing collaborations
Offers manufacturing collaborations for selected industrial and academic partners.
CDMO: development & manufacturing
Clinical trial management
Runs and manages clinical trials in-house from Phase I through Phase III.
Bioanalytics
Lists bioanalytics as one of its service areas.
Assays & in vitro testing
Preclinical development
Couples targeting ligands with bioactive payloads and tests the resulting targeted drugs in preclinical models.
Clinical development
Runs and manages clinical trials in-house from Phase I through Phase III.
Discovery collaborations
Offers flexible collaboration structures for screening binders against selected targets.
DNA-encoded library screening
Uses proprietary DNA-encoded chemical libraries for drug discovery screening.
R&D discovery
Runs discovery collaborations through Philochem for screening binders against selected targets using proprietary libraries and platforms.
Clinical trials
Runs and manages clinical trials in-house across Phase I through Phase III.
Capabilities
- Processes
- Small molecule · Antibody · Peptide · Cell therapy · Recombinant protein · Antibodies · Peptides · Bioanalysis · Small molecules
- Capacity
- More than one billion compounds · More than 100 billion members · Two GMP manufacturing facilities near Siena · Up to Phase III clinical trials · 21 clinical trials · More than one billion compounds in DNA-encoded chemical libraries · More than 100 billion members in antibody phage libraries · More than 100 billion members in short cyclic peptide phage libraries
Equipment
- DNA-encoded chemical libraries
- Antibody phage libraries
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
GLPSelf-reported
ISO 9001:2015Self-reported
Industries served
- Biotech
- Pharmaceuticals
- Oncology
Company
- Type
- CRDMO
- Founded
- 1996
Locations
- Based in
- Sovicille, Italy
- Sites
- Siena, Italy · Monteriggioni (SI), Italy · Milano, Italy · Otelfingen, Switzerland · Sovicille, Italy · Monteriggioni, Italy · Zürich, Switzerland
Contacts
- Phone
- (+39) 0577.1781.6
Similar labs
Work here? Claim this listing